Print

Purpose

REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female aged ≥ 18 - With post-COVID condition - Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test) - Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE - Able to provide signed informed consent (by the subject or his/her legally authorized representative) - Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent

Exclusion Criteria

  • Neurological disorders prior to COVID-19 diagnosis - With pre-existing terminal illness - With known immune disease - Is pregnant or breastfeeding - Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening - Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period - Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases - Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

Study Design

Phase
Study Type
Expanded Access

Recruiting Locations

D&H National Research Center #1
Miami, Florida 33169
Contact:
Joseph Durandis, M.D.
786-375-6210
drjdurandis@nrcinc.com

Myrak Research Center Inc.
Miami Lakes, Florida 33014
Contact:
Danay Gonzalez
305-825-1400
dgonzalez@myrakresearchcenter.com

More Details

NCT ID
NCT07332338
Status
Available
Sponsor
StemCyte, Inc.

Study Contact

Clinical Research Department
886-2-26013013
expandedaccess@stemcyte.com

Detailed Description

A total of 30 subjects with post-COVID will be enrolled.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.